U.S. Markets closed

Biostage, Inc. (BSTG)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
4.4800-0.1700 (-3.66%)
At close: 03:50PM EDT

Biostage, Inc.

84 October Hill Road
Suite 11
Holliston, MA 01746
United States
774 233 7300

Full Time Employees6

Key Executives

NameTitlePayExercisedYear Born
Mr. Yu HongPres157.95kN/A1973
Dr. William L. Fodor Ph.D.Chief Scientific Officer322.15kN/A1959
Mr. David GreenInterim CEO & ChairmanN/AN/A1964
Mr. Peter A. Pellegrino Jr.Interim VP of Fin.N/AN/A1975
Dr. Shunfu Hu Ph.D.VP of Bus. Devel. & OperationsN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Biostage, Inc., a biotechnology company, offers products to cure patients of cancers, injuries, and birth defects of the gastro-intestinal tract and the airways. The company is engaged in developing Biostage Esophageal Implant for the treating esophageal cancer. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2009 and is headquartered in Holliston, Massachusetts.

Corporate Governance

Biostage, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.